DELTA-FLY-PHARMA
7.2.2024 12:01:32 CET | Business Wire | Press release
Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.
A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States. Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.
DFP-14927 is an amide bond of DFP-10917 to a carboxylic acid at the end of polyethylene glycol (PEG) with a molecular weight of 40,000, and it is extremely stable in human blood after intravenous administration, allowing for weekly treatment regimen. DFP-14927 is a drug delivery system (DDS) with a mechanism that allows selective release of DFP-10917 into cancer tissues by amidolysis of proteases that are highly expressed in them.
Compared to high molecular weight antibody-drug conjugates (ADCs), medium-sized PEG covalent conjugates are known to have retention in blood vessels around cancer and cancer cell membranes and higher permeability into tumors, and therefore, the concentration of DFP-10917 in cancer tissue can be measured by conventional analysis without the use of radioisotope technology.
Soon after the expected effective concentration of DFP-10917 in cancer tissue is confirmed in the study, we plan to conduct an expanded Phase I study, equivalent to a Phase II clinical trial, in patients with colorectal cancer who have failed existing approved drugs.
The composition of matter patent for DFP-14927 has been granted in the United States, Europe, Asian countries and others, which will enable global marketing of DFP-14927.
In collaboration with leading oncology hospitals in the U.S., we are considering the development of DFP-14927 in haematological cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in addition to solid tumors.
For our future global development and marketing strategy, we are considering collaboration with a major global pharmaceutical company that has strength and expertise in the oncology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207063856/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE adds Data Benchmarking, AI Capabilities and ISO certification9.9.2026 10:00:00 CEST | Press release
1NCE Insights now offers access to benchmarks from 30,000+ global deployments across 17 industries, enabling customers to compare their solutions to real-world peers. Launch of 1NCE AI, a unified API gateway providing access to leading AI models with centralized vendor management. ISO/IEC 27001:2022 certified infrastructure, reflecting 1NCE's commitment to data security. 1NCE announced a new upgrade of 1NCE Insights and the launch of 1NCE AI. Both expand 1NCE's foundational platform services, giving customers greater intelligence and control over connected device data. The new 1NCE Insights upgrade gives customers access to aggregated benchmark data from 30,000+ deployments. They can compare network usage patterns, battery performance, hardware choices and traffic optimization against real-world peers, enabling faster product development. 1NCE AI provides access to leading AI models through a unified API gateway, eliminating vendor fragmentation. The service is Germany-hosted and fully
HSCALE Secures Landmark Strategic Deal With Major US Cloud Provider for Hyperscale Data Centre Campus in Spain9.9.2026 09:00:00 CEST | Press release
The deal represents over US$1 billion in contract value which underpins the expansion and development of one of Spain's largest data centres currently under construction Major long-term agreement with a leading global cloud platform provider. First Ready-for-Service date in 2027. Project represents approximately US$1 billion of capex investment, strengthening and further cementing Spain's position in Europe's AI and cloud economy HSCALE, the pan-European hyperscale data centre platform, announced today a major strategic deal with a significant global cloud provider to deliver large-scale, high-performance digital infrastructure in a strategic metropolitan area within the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909242953/en/ HSCALE's CCO Paul Berry-Selwood The agreement is a defining milestone for HSCALE and anchors the development of a next-generation campus designed for the demanding requirement
Fighting Fire with Fire: Mobileum and Apate Shut Down Scam Operations From the Inside Out9.9.2026 09:00:00 CEST | Press release
AI-powered conversational agents help CSPs go beyond call and message blocking, disrupting fraudsters before they reach real customers. Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and Apate.ai (“Apate”) have announced a partnership that equips communications service providers (CSPs) with advanced AI-powered fraud prevention capabilities designed to detect, disrupt, and investigate scam call operations. According to the Global Anti-Scam Alliance, scammers stole an estimated $442 billion in 2025, with phone calls, text messages and emails being the top three communication channels used by scammers. Through the integration of Mobileum’s Active Intelligence Platform with Apate's conversational AI agents, CSPs can now move beyond traditional call blocking and take a more proactive role in disrupting scam activity. Rather than simply preventing suspicious calls, messages and other communications from reaching customers, the solution engages fraud
FinXP Partners with Thredd to Strengthen Multi-Region Card Issuing Capabilities9.9.2026 09:00:00 CEST | Press release
Mastercard principal member FinXP is combining its issuing capabilities with Thredd’s AI-first issuer-processing platform to support scalable debit card programmes across Europe and future growth markets FinXP, a European payment infrastructure provider, has partnered with Thredd, the AI-first issuer processing platform, to strengthen FinXP’s card issuing capabilities and support the next phase of its embedded finance offering. The partnership with Thredd will enable FinXP to enhance its debit card programmes with a modern issuer-processing stack, supporting tokenisation, provisioning, risk and fraud prevention, card controls, and automated back-office operations. FinXP will retain control of its own ledger and programme strategy, while Thredd will provide the programme infrastructure needed to support secure, scalable and flexible card issuing across multiple regions. FinXP has been issuing cards for five years and already supports businesses with accounts, payments, collections, payo
KONGSBERG Selects Echodyne MESA Radar for Counter-UAS Weapon Systems9.9.2026 08:00:00 CEST | Press release
Low-SWaP, precision-tracking radar integrated with PROTECTOR RS4 and RS6 remote weapon stations to strengthen detection-to-defeat performance against drones Echodyne, the radar platform company, today announced that KONGSBERG has selected Echodyne's MESA® radar platform for a range of air and surface applications. Among the first use cases, KONGSBERG has integrated MESA radar into the PROTECTOR RS4 and PROTECTOR RS6 remote weapon stations (RWS), adding the precision radar data needed to turn the world's most widely deployed RWS family into a highly effective counter-unmanned aircraft system (C-UAS) effector. The selection pairs KONGSBERG's proven weapon-station architecture and Collaborative Fire Control capabilities with Echodyne's compact, solid-state radar. The result is a scalable approach for adding high-fidelity detection, tracking and targeting data to static, crewed and uncrewed platforms without the size, weight and power demands traditionally associated with high-performance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom